Published in Gene Therapy Weekly, November 11th, 2004
The kinase platform is built utilizing QTL's patented superquenching polymer technology, which delivers universal mix and measure assays that do not require antibodies or radioactive labels. The platform is compatible with standard fluorescent instrumentation and works with peptide or protein substrates. The kinase assays are used to target the molecular processes of the cell and to develop new future treatments for cancer, diabetes and other diseases.
The first four kinase assays are:
-PKC-alpha, targeted at drugs...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.